OR WAIT null SECS
New organization to focus on advancing genetic medicines.
Neurogene Inc., a biotechnology company, and Neoleukin Therapeutics, an organization focused on protein development, have agreed to terms on a merger in an all-stock transaction. According to a company press release, the combined effort is set to focus on advancing Neurogene’s pipeline of differentiated genetic medicines, including NGN-401, a clinical-stage product for Rett syndrome, which uses novel gene regulation technology for a potential best-in-class profile. Upon stockholder approval, the combined company is expected to operate under the Neurogene Inc. brand.
“We are excited to announce our planned merger with Neoleukin, which we believe is a transformative step forward in our mission to bring life-changing genetic medicines to the patients and families impacted by devastating neurological diseases,” said Rachel McMinn, PhD, Founder, CEO, Neurogene, in the company press release. “This transaction is expected to bolster our ability to progress our differentiated pipeline, including our clinical-stage program in Rett syndrome which contains our novel, proprietary EXACT technology. We believe EXACT represents a meaningful technological advance for the gene therapy field, allowing us to develop therapeutic product candidates for complex diseases with attractive market opportunities not addressable with conventional gene therapy.
Reference: Neurogene and Neoleukin Announce Definitive Merger Agreement. Neoleukin. July 18, 2023. Accessed July 21, 2023. https://investor.neoleukin.com/news-releases/news-release-details/neurogene-and-neoleukin-announce-definitive-merger-agreement